Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution - Inspira Technologies Oxy (NASDAQ:IINN

Core Viewpoint - Inspira Technologies has announced a definitive agreement for a registered direct offering of ordinary shares, aiming to raise approximately $1.8 million to support its strategic initiatives and operations [1][2][6]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, resulting in gross proceeds of about $1.8 million [2]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - Inspira has entered into a SEPA with YA, allowing the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion [4]. - There are no minimum purchase requirements under the SEPA, and the company is not obligated to draw on this facility [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with products like the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 [8]. - The company is positioned as an attractive platform within the life-support and MedTech landscape, supported by a growing IP portfolio and multiple cleared products [8].